-
Zhittya Genesis Medicine, Inc. FGF-1, Dan Montano CEO
Lately I’ve been exchanging emails and phone calls with Dan Montano, CEO of Zhittya Genesis Medicine, Inc. Googled information on him is all over the map. I’m considering investing in this miracle drug his company offers which he seems to truly believe will cure PD following the results of animal studies. Human studies should begin in a few months, he says. If you know anything about him or his company, I’m all ears.
-
4 Replies
-
Today I spoke with a trusted financial advisor who used his resources to research Mr. Montano and his company. He mentioned a “shady past” in Mr. Montano’s background. In terms of investing any money in his company, Zhittya Genesis Medicine, Inc. he said, “If it were me I’d run away, and run away fast.”
-
Hi Steve, Although this turned out to be a dead end, I really appreciate your leaving no stone unturned and willingness to seek out new possibilities.
-
Zhittya Genesis Medicine announced in its April Update that it has a regulatory pathway to start its Phase I, Proof of Concept clinical trial to utilize FGF-1 to treat Parkinson’s Disease. Dan Montano CEO of Zhittya Genesis Medicine stated that he hopes by the end of 2020 to have human clinical data if the infusion of FGF-1 into humans is safe and has any benefits for Parkinson’s suffers.
-
Any news from Mexico how the trial is going ?
Log in to reply.